Major depressive disorder, single episode, moderate
Methodology & AI Transparency ⓘ
Major depressive disorder, single episode, moderate Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinical triage of Major depressive disorder, single episode, moderate (F32.1) in Depression & Mood relies on medical mimic exclusion in Major depressive disorder, single episode, moderate (F32.1: (thyroid), guiding step-wise therapeutic adjustments toward Serum Vitamin D in Major depressive disorder, single episode, moderate (F32.1: & RBC Folate) (25(OH)D 40 – 65 ng/mL (F32.1)).
- 2 Real-world patient consensus: Clinical coding for Major depressive disorder, single episode, moderate uses ICD-10 F32.1 across Depression & Mood specialty care.
- 3 Typical cash cost range: Clinicians assessing Major depressive disorder, single episode, moderate focus on hypothalamic-pituitary-adrenal (HPA) axis in Major depressive disorder, single episode, moderate (F32.1: cortisol hyperactivity) and targeted history.
- 4 Top reported side effects / signs: Key Depression & Mood biomarkers for Major depressive disorder, single episode, moderate (F32.1): TSH & Free in Major depressive disorder, single episode, moderate (F32.1: T4 Rule-Out) & Serum Vitamin D in Major depressive disorder, single episode, moderate (F32.1: & RBC Folate) (25(OH)D 40 – 65 ng/mL (F32.1)).
Ask our AI Specialists anything about Major depressive disorder, single episode, moderate
What Is Major depressive disorder, single episode, moderate?
Clinical triage of Major depressive disorder, single episode, moderate (F32.1) in Depression & Mood relies on medical mimic exclusion in Major depressive disorder, single episode, moderate (F32.1: (thyroid), guiding step-wise therapeutic adjustments toward Serum Vitamin D in Major depressive disorder, single episode, moderate (F32.1: & RBC Folate) (25(OH)D 40 – 65 ng/mL (F32.1)).
Pathophysiology, Underlying Causes & Clinical Presentation
Major depressive disorder, single episode, moderate (F32.1) alters depression & mood homeostasis through hypothalamic-pituitary-adrenal (HPA) axis in Major depressive disorder, single episode, moderate (F32.1: cortisol hyperactivity); clinical remission targets Serum Vitamin D in Major depressive disorder, single episode, moderate (F32.1: & RBC Folate) within 25(OH)D 40 – 65 ng/mL (F32.1).
Common Symptoms & Clinical Signs
- • Presentation of Major depressive disorder, single episode, moderate (F32.1): slowed concentration, indecisiveness, in Major depressive disorder, single episode, moderate (F32.1: and physical heaviness)
- • Secondary Major depressive disorder, single episode, moderate clinical sign: loss of interest in Major depressive disorder, single episode, moderate (F32.1: or pleasure in)
- • Symptom flares in Major depressive disorder, single episode, moderate correlating with TSH & Free in Major depressive disorder, single episode, moderate (F32.1: T4 Rule-Out) deviation outside TSH 0.8 – 2.5 mIU/L (F32.1)
- • Functional depression & mood impact requiring medical mimic exclusion in Major depressive disorder, single episode, moderate (F32.1: (thyroid) evaluation (F32.1)
Major depressive disorder, single episode, moderate Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F32.1 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Depression, Bipolar & Mood Disorders | NLM Clinical Tables |
| Diagnostic / Lab Marker: TSH & Free in Major depressive disorder, single episode, moderate (F32.1: T4 Rule-Out) | TSH 0.8 – 2.5 mIU/L (F32.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Vitamin D in Major depressive disorder, single episode, moderate (F32.1: & RBC Folate) | 25(OH)D 40 – 65 ng/mL (F32.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: PHQ-9 Symptom Severity in Major depressive disorder, single episode, moderate (F32.1: Score) | < 4 (clinical remission) (F32.1) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Major depressive disorder, single episode, moderate
Treatment selection for Major depressive disorder, single episode, moderate depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Major depressive disorder, single episode, moderate)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake: What a 10,039-Participant Study Found Higher doses of SSRIs appear slightly more effective in depression. The American journal of psychiatry • 2016-02-01 • Meta-Analysis | N = 10,039 | 99/100 | PMID 26552940 ↗ |
| New Insights on Pharmacological and non-pharmacological treatments for depression in: What a 10,991-Participant Study Found Herbal medicine and mirtazapine had no significant difference in overall risk of side effects compared with placebo. Psychiatry research • 2019-11-15 • Meta-Analysis | N = 10,991 | 99/100 | PMID 31627074 ↗ |
| New Insights on Antidepressants for the treatment of adults with depression in the maintenance: What a 9,384-Participant Study Found Compared to placebo, venlafaxine was associated with a lower incidence of dizziness, while desvenlafaxine, sertraline, and vortioxetine were associated with a higher incidence of nausea/vomiting. Molecular psychiatry • 2023-01-15 • Meta-Analysis | N = 9,384 | 99/100 | PMID 36253442 ↗ |
| New Insights on Modeling the efficacy of a novel antidepressant zuranolone for: What a 8,735-Participant Study Found Primary side effects related to zuranolone included somnolence, headache, dizziness, and sedation, with no severe safety signals observed. Journal of affective disorders • 2026-01-01 • Meta-Analysis | N = 8,735 | 99/100 | PMID 40876640 ↗ |
| New Insights on Major outcomes in high-risk hypertensive patients randomized to: What a 9,048-Participant Study Found Thiazide-type diuretics are superior in preventing 1 or more major forms of CVD and are less expensive. JAMA • 2002-12-18 • Randomized Controlled Trial | N = 9,048 | 96/100 | PMID 12479763 ↗ |
Major depressive disorder, single episode, moderate Patient Community & “People Like Me” Threads
Filter Major depressive disorder, single episode, moderate community threads and patient logs by age, biological sex, dosage, and treatment duration.